

CSU IBC Meeting – APPROVED MINUTES

Meeting title	CSU IBC Meeting February 2026
Date	February 11, 2026
Convened at	8:35am
Location	TMI Rm 222
Open or closed meeting (If closed, why?)	The meeting was open for the entire time.
Review of prior meeting minutes	January 21, 2026 meeting minutes were approved as written.
Adjournment	9:25am
Recorded by	C. Johnson

Attendees

Check if Attending (Members):	Check if Attending (Alternate Members):
☐ Jessica Ayers, Animal expert	☐ Lon Kendall, Director LAR
☒ Donald Bade, Unaffiliated	
☒ Angela Bosco-Lauth, Associate Chair	
☒ Chaoping Chen, Chair	
☒ Jason Cummings, lab representative	
☐ Dan Frazen, Unaffiliated	
☒ Brendan Podell, Mycobacteria specialist	
☒ Ann Powers, Virology	
☒ Robyn Roberts, Plant expert	
☒ Joanie Ryan, Assistant Biosafety Director	☐ Rebecca Moritz, Biosafety Office Director*
☒ Tony Schountz, Virology	☒ Christine Johnson, IBC/IRE Manager, Alternate-at-Large*
Quorum = 6 voting members; _9_ in attendance	*non-voting at this meeting
Non-Voting Members:	
☐	
☐ Joni Van Sickle, Occupational Health Coord.	
ORCC Staff (non-voting):	
☐ Michelle Ramey, Assistant Compliance Coord.	☐ Sonia Aleman Rivera, Assistant Biosafety Officer
☒ Nicole Marlenee, Biosecurity Specialist	☒ Kelly Kim, Assistant Biosafety Officer
☒ Scott Van Scotter, Biosafety Trainer	
Additional Guests:	
Mario Arango, OGC	

Quorum was maintained throughout. Any member with a conflict of interest left the meeting during discussion and/or committee determination on the conflicted items.

1. Review of January 21, 2026 IBC meeting minutes

The minutes were unanimously approved as written.

2. Agent/Project Review

a. PI name/Lab	Flynn Lab
Project Number and Title	26-005B: Mitigating cellular stress to improve translational applications for human health and degenerative diseases
Viral Vector Forms	• Viral Vector Registration Form-AdEasy • Viral Vector Registration Form-AAV Serotype 5
NIH Guidelines Section	III-D-1; III-D-2; III-D-3; III-E; III-E-1
Proposed containment conditions (BSL, ABSL, etc.)	BSL2
Discussion	For the Viral Vector Form - AdEasy: • Virus Type should be changed from AAV to adenoviruses. For the Project: • Under Description of Experimental and Procedural Details, please add the contact time for chemical disinfectants listed. Please confirm which materials will be autoclaved.
Verification of training	All personnel need to complete the Annual Biosafety Training.
Verification of facilities	A lab visit is required for the new lab space.
Motion	A motion was made to approve the agent and project with modifications described above (see Discussion)
Vote	The motion was unanimously approved.
b. PI name/Lab	Podell Lab
Project Number and Title	26-009B: Vaccine efficacy in the guinea pig model of tuberculosis
Agents used	• Mycobacterium bovis BCG • M. tuberculosis Erdman
NIH Guidelines Section	III-D-4
Proposed containment conditions (BSL, ABSL, etc.)	BSL3/ABLS3
Discussion	The committee requested clarification regarding the route of administration for the mRNA vaccine.
Verification of training	The new personnel need to finish their BSL3 training.
Verification of facilities	The lab is up to date on lab inspections.
Motion	A motion was made to approve the agent and project with modifications described above (see Discussion)
Vote	The motion was unanimously approved.

3. Amendments requiring full IBC review

c. PI name/Lab	Stenglein Lab
Project Number and Title	19-085B: Analysis of bunyavirus reassortment
Agents used	• Bunyamwera virus • LaCrosse virus • Kairi virus • Snowshoe hare virus • Inkoo virus • Tahyna virus • California encephalitis virus • Jamestown canyon virus • Trivittatus virus
NIH Guidelines Section	III-D-3
Proposed containment conditions (BSL, ABSL, etc.)	BSL2/BSL3
Amendment request	Additional details and updated procedures
Discussion	The IBC requested clarification regarding what portions are happening in BSL2 vs BSL3, including the differences in PPE.
Motion	A motion was made to approve the amendment request with modifications described above (see Discussion).
Vote	The motion was unanimously approved.

4. New Business

a. IBC Membership update

- Associate Chair – Leadership has requested that we formalize an Associate Chair role for the IBC. Angela Bosco-Lauth was appointed as the IBC Associate Chair, she will serve as a backup for the Chair.
- Candidates for Jean Peccoud’s replacement – Dr. Peccoud left CSU at the end of year, leaving an opening in synthetic biology expertise. The IBC/IRE Manager consulted with department heads for recommendations for a replacement. Dr. Joshua Chan was one of the recommendations and has expressed an interest in serving on the committee. The IBC discussed his nomination and voted to move forward with requesting VPR approval.

5. Unfinished Business

a. NIH Initiative to Modernize and Strengthen Biosafety Oversight

(<https://osp.od.nih.gov/policies/biosafety-and-biosecurity-policy#tab2/>)

The 5th listening session is scheduled for Feb. 12th. This is the region the CO is in. The IBC/IRE Manager encouraged the committee members to attend if they can.

6. Closed Session

- No items to discuss

7. Reports

a. Coordinator's Report	1. Next IBC meeting: Wednesday, March 11, 2026
b. Biosafety Office Report	1. Inspections update: there was a surprise DOT inspection on 2/5; everything went well. 2. Incident Reports: there were no incidents involving rDNA this month

8. Public Comment

None

9. Items to be read into the minutes

a. Items Reviewed at Previous IBC Meeting and Approved After Modification were completed	a. Thamm Lab (amendment) Project: <u>Cellular Immunotherapy for Canine Cancers</u> ; (19-038B); BSL2/ABSL2; NIH Guidelines category non-exempt rDNA: III-D-4 b. Halstead Lab Project: <u>Investigating totipotency in bovine embryos and stem cells</u> (25-074B); BSL2; NIH Guidelines category non-exempt rDNA: III-E Project: <u>Modeling early developmental failure in embryoids</u> (25-075B); BSL2; NIH Guidelines category non-exempt rDNA: III-E
---	--